Arkolith/Insider Trading/GENB/Form 4

Flagship Pioneering Fund VI, L.P.

10% OwnerGenerate Biomedicines, Inc. (GENB) · full profile →Form 4 · filed Mar 2, 2026
Net Buying
Open-Market Buys
$75.0M
Open-Market Sells
$0
Net Open-Market Flow
$75.0M
Transactions
19
8 non-derivative · 11 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Buy(P)1.6M$16.00$25.0M15.3M
Mar 2, 2026Conversion(C)2.8M——2.8M
Mar 2, 2026Conversion(C)2.8M——2.8M
Mar 2, 2026Conversion(C)12.7M——12.7M
Mar 2, 2026Conversion(C)987K——987K
Mar 2, 2026Conversion(C)13.7M——13.7M
Mar 2, 2026Buy(P)1.6M$16.00$25.0M1.6M
Mar 2, 2026Buy(P)1.6M$16.00$25.0M4.3M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Conversion(C)1.5M—$00
Mar 2, 2026Conversion(C)844K—$00
Mar 2, 2026Conversion(C)1.3M—$00
Mar 2, 2026Conversion(C)3.0M—$00
Mar 2, 2026Conversion(C)2.1M—$00
Mar 2, 2026Conversion(C)2.5M—$00
Mar 2, 2026Conversion(C)1.3M—$00
Mar 2, 2026Conversion(C)2.1M—$00
Mar 2, 2026Conversion(C)18.5M—$00
Mar 2, 2026Conversion(C)17.0M—$00
Feb 26, 2026Grant(A)30K—$030K

Transaction Codes

P
Open-market purchase
C
Conversion of a derivative
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-085855) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML